In-Licensed Drug Products Can Be a Signal of Future Outsourcing
Of the more than 230 New Molecular Entities (NMEs) approved between 2003-2013, over one-third were in-licensed by the sponsor receiving the approval. Recent research by our team showed an unexpected and significant difference in manufacturing status between products originally discovered in-house and those in-licensed from external partners. During this period 66% of in-licensed NMEs were either outsourced completely or partially, compared to 44% for internally discovered candidates.
According to the latest PharmSource Trend Report, Opportunity Knocks: In-Licensed Drug Products Can Signal Outsourcing Opportunity, in-licensing of NMEs is an important positive signal to the CDMO sector that a candidate is likely to be successful and its manufacture is likely to be outsourced.
More information on Opportunity Knocks: In-Licensed Drug Products Can Signal Outsourcing Opportunity is available here or by calling PharmSource at +1-703-383-4903.